WO2025008467A2 - Utilisation d'un marqueur ou d'un ensemble de marqueurs pour déterminer le risque qu'un individu présente une fonction hépatique réduite - Google Patents

Utilisation d'un marqueur ou d'un ensemble de marqueurs pour déterminer le risque qu'un individu présente une fonction hépatique réduite Download PDF

Info

Publication number
WO2025008467A2
WO2025008467A2 PCT/EP2024/068885 EP2024068885W WO2025008467A2 WO 2025008467 A2 WO2025008467 A2 WO 2025008467A2 EP 2024068885 W EP2024068885 W EP 2024068885W WO 2025008467 A2 WO2025008467 A2 WO 2025008467A2
Authority
WO
WIPO (PCT)
Prior art keywords
substances
marker
valine
apolipoprotein
liver function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2024/068885
Other languages
English (en)
Other versions
WO2025008467A3 (fr
Inventor
Sebastian DE JEL
Frank STÄMMLER
Sebastian RÖTZER
Andrew Robertson
Johannes EIGLSPERGER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Numares AG
Original Assignee
Numares AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numares AG filed Critical Numares AG
Publication of WO2025008467A2 publication Critical patent/WO2025008467A2/fr
Publication of WO2025008467A3 publication Critical patent/WO2025008467A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Definitions

  • the present invention relates to the in-vitro use of a marker or a marker set for determining the risk of an individual to have a reduced liver function according to the preamble of claim 1 , to the further medical use of such a marker or a marker set according to the preamble of claim 13, and to an analysis method for determining the risk of an individual to have a reduced liver function according to the preamble of claim 14.
  • liver function is broad, given the vast array of physiological and biochemical functions the organ carries out, chiefly biliary synthesis for fatty acid digestion, metabolism of carbohydrate, protein and lipids, synthesis of protein and detoxification. Thus, hepatocyte function is paramount to physiological survival.
  • liver function numerically, as opposed to the glomerular filtration rate of the kidney or the ejection fraction of the heart.
  • a number of blood tests are available which reflect the general damage to hepatocytes - mostly products of hepatic metabolic pathways and enzymes - the most common in clinical practice being serum aminotransferases, bilirubin, alkaline phosphatase, albumin, and prothrombin time. These tests are commonly grouped together under the umbrella term ‘Liver Function Tests’ which is misleading, since most are unable to reflect how well the liver is functioning and abnormal values can be due to diseases unrelated to the liver.
  • these tests may be normal in patients with advanced liver disease yet abnormal in asymptomatic healthy individuals [1 -3].
  • the combination of detection of serial changes in this test panel interpreted together with patient symptomatology can assist in monitoring progression or remission of disease and can trigger subsequent and more advanced diagnostic testing.
  • ICG indocyanine green tracer test
  • Child-Pugh score A simpler measure of global liver function lies with the Child-Pugh score, particularly in patients having cirrhosis. Originally designed to assess the risk of non-shunt operations in patients with cirrhosis (namely transection of the esophagus for bleeding esophageal varices), it was further validated to stratify the risk of portacaval shunt surgery in patients with cirrhosis. It was also later demonstrated to correlate with survival in patients not undergoing surgery. Additionally, Child-Pugh class is also associated with the likelihood of developing complications of cirrhosis, such as variceal hemorrhage. Components of the modified Child-Pugh classification of the severity of liver disease are degree of ascites, the serum concentrations of bilirubin and albumin, the prothrombin time, and the degree of encephalopathy.
  • Child-Pugh score (sometimes also referred to as Child-Turcotte-Pugh score) of 5 to 6 is considered Child-Pugh class A (well-compensated disease, 10 % postoperative mortality risk), a score of 7 to 9 is class B (significant functional compromise, 30 % postoperative mortality risk), and a score of 10 to 15 is class C (decompensated disease, 82 % postoperative mortality risk).
  • Child-Pugh class A well-compensated disease, 10 % postoperative mortality risk
  • class B significant functional compromise, 30 % postoperative mortality risk
  • class C decompensated disease, 82 % postoperative mortality risk
  • an accurate Child- Pugh score as an estimation of global liver function has significant utility in perioperative planning of patients with cirrhosis, resource management, prioritization of liver treatment, identification of those at risk of decompensated liver failure, and general prognostication.
  • the Child-Pugh score is currently embedded in the treatment algorithm for hepatocellular carcinoma (HCC) [12] and is a feature of liver transplant eligibility [13].
  • Preserved liver function refers to Child-Pugh A without any ascites, and hence “reduced liver function” being Child-Pugh A with ascites or Child-Pugh B or C.
  • Preserved liver function group is considered a condition required to obtain optimal outcomes, and this prerequisite applies to all treatment options, whereby non-preserved/reduced liver function is deemed terminal stage D disease [17], This stratification process still requires an accurate measurement of Child-Pugh class with its associated diagnostic difficulties.
  • US 2020/0378991 A1 describes biomarkers and biomarker panels useful for diagnostic methods evaluating liver disease status in a subject, monitoring liver disease, distinguishing between liver diseases, treating subjects evaluated by diagnostic methods of the invention, providing diagnostic tests for evaluating liver disease status in a subject, and kits therefor.
  • the biomarkers are chosen from bile acids, free fatty acids, amino acids, and carbohydrates listed in Table 1 of this U.S. patent application.
  • a specific example relates to a biomarker panel comprising palmitic acid (C16:0), palmitic acid (C16:0)/palmitoleic acid (C16:1 n7) ratio, tyrosine, fructose, fructose/glucose ratio, glycochenodeoxycholic acid (GCDCA), and glycocholic acid (GCA).
  • US 2017/0370954 A1 describes biomarkers of nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), and fibrosis and methods for diagnosis (or aiding in the diagnosis) of NAFLD, NASH and/or fibrosis. Additionally, methods of distinguishing between NAFLD and NASH, methods of classifying the stage of fibrosis, methods of determining the severity of liver disease, methods of determining the severity of liver disease or fibrosis, and methods of monitoring progression/regression of NASH, NAFLD, and/or fibrosis are described. In this context, this U.S. patent application lists scores of various substances.
  • a specific example is a biomarker or biomarker set selected from the group consisting of 5-methylthioadenosine (5-MTA), glycine, serine, leucine, 4-methyl-2- oxopentanoate, 3-methyl-2-oxovalerate, valine, 3-methyl-2-oxobutyrate, 2-hydroxybutyrate, prolylproline, lanosterol, tauro-beta-muricholate, and deoxycholate.
  • 5-MTA 5-methylthioadenosine
  • the marker is chosen from a first group consisting of high-density lipoprotein, apolipoprotein A1 , valine, and lactate.
  • the marker set comprises or consists of at least two (e.g., 2, 3, 4, 5, 6) substances that are chosen from a second group consisting of high-density lipoprotein (HDL), apolipoprotein A1 , valine, pyruvate, lactate, myo-inositol, and anhydrosorbitol.
  • HDL high-density lipoprotein
  • the concentration of the marker or of the substances contained in the marker set is determined in a body fluid obtained from a patient.
  • This concentration determination can be carried out by any appropriate measuring or analysis method, such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry, high-performance liquid chromatography (HPLC), infrared spectroscopy such as Fourier-transform infrared (FT-IR) spectroscopy, clinical chemistry, and immunodiagnostics.
  • NMR nuclear magnetic resonance
  • HPLC high-performance liquid chromatography
  • FT-IR Fourier-transform infrared
  • An alteration of concentration of the individual marker or of at least two substances of the marker set with respect to the concentration in a control group or an alteration of a concentration ratio between at least two substances with respect to the concentration ratio of the same substances in a control group was correlated in a statistically significant way with a reduced liver function at the time of analysis (i.e., enabling a distinction between individuals having a preserved liver function (Child-Pugh class A without any ascites) and individuals having a reduced liver function (Child-Pugh class A with ascites or Child-Pugh class B or C).
  • the use of the biomarkers can also be described as use for classifying an individual into a group of preserved liver function (healthy group; control group) or a group of reduced liver function (diseased group, patient group or case group). I.e., the use is directed to diagnose in a patient or individual a reduced liver function according to the abovegiven definition.
  • AUC area under the curve
  • ROC receiver operating characteristic
  • the AUC value of ROC plots is an aggregated metric that evaluates how well a logistic regression model classifies positive and negative outcomes at all possible cut-offs. It can range from 0 to 1.0.
  • An AUC value of 0 represents a prediction of the opposite of the trained correlation.
  • An AUC value of 0.5 represents a random prediction.
  • An AUC value of higher than 0.5 represents a classification of an event as fulfilling the trained correlation, wherein higher values represent better classification.
  • the resulting AUC values were significantly above 0.75, in most cases 0.8 or higher or even 0.85 or higher.
  • biomarkers and the marker sets were tested against a training dataset and a test dataset. After all training and test processes, high-density lipoprotein, apolipoprotein A1 , valine, and lactate turned out to be valid biomarkers for the underlying question (i.e., distinguishing individuals having a preserved liver function versus individuals having a reduced liver function). In this context, these biomarkers were very well appropriate biomarkers if used individually.
  • high-density lipoprotein, apolipoprotein A1 , valine, lactate, pyruvate, and fumarate turned out to be particularly valid biomarkers for the underlying question, provided that the concentration of at least two of these biomarkers was determined at the same time (i.e., in one or more body fluid samples from the same patient obtained at the same time point).
  • the concentration determination can be made with a method being able to determine the concentration of the substances by a single measurement or by a method requiring more than one measurement for such determination.
  • NMR spectroscopy is particularly appropriate for such a concentration determination since it enables a highly accurate concentration determination of multiple substances in a body fluid by a single measurement in a very short measuring time.
  • the concentration of the substances is standardized to the concentration of another substance that is naturally present in the sample.
  • This other substance may also be listed in the first group or the second group of substances. In an embodiment, this other substance does not belong to the first or the second group as defined above.
  • the marker set comprises at least one substance chosen from the second group and being different from high-density lipoprotein and apolipoprotein A1 if the marker set comprises any of high-density lipoprotein and apolipoprotein A1 as a first of the at least two substances.
  • the concentrations of HDL and apolipoprotein A1 in a body fluid are typically closely interrelated with each other so that both substances can be exchanged against each other for many applications. Therefore, the marker set is particularly appropriate for determining the risk of an individual of having a reduced liver function if HDL and apolipoprotein A1 are not used as the only substances in the marker set.
  • the marker is HDL or apolipoprotein A1 .
  • HDL as biomarker showed an AUC value of 0.86 in the training dataset (confer Figure 1A) and of 0.84 in the test dataset (confer Figure 1 B).
  • HDL and consequently the closely related apolipoprotein A1 are a particularly appropriate single biomarker for determining the risk of an individual of having a reduced liver function. The accuracy of such risk determination can even be increased if HDL is combined with at least one other biomarker, as will be explained in later sections of the present disclosure.
  • the marker is valine.
  • a biomarker showed an AUC value of 0.79 in the training dataset (confer Figure 2A) and of 0.75 in the test dataset (confer Figure 2B).
  • valine is a particularly appropriate single biomarker for determining the risk of an individual of having a reduced liver function. The accuracy of such risk determination can even be increased if valine is combined with at least one other biomarker, as will be explained in later sections of the present disclosure.
  • the marker is lactate.
  • Such a biomarker showed an AUC value of 0.78 in the training dataset (confer Figure 3A) and of 0.76 in the test dataset (confer Figure 3B).
  • pyruvate is a particularly appropriate single biomarker for determining the risk of an individual of having a reduced liver function. The accuracy of such risk determination can even be increased if pyruvate is combined with at least one other biomarker, as will be explained in later sections of the present disclosure.
  • the marker set comprises or consists of HDL or apolipoprotein A1 as a first of the at least two substances and valine as a second of the at least two substances.
  • a biomarker set showed an AUC value of 0.87 in the training dataset (confer Figure 4A) and of 0.85 in the test dataset (confer Figure 4B).
  • combining HDL and valine as biomarkers in the marker set significantly increases the sensitivity of determination of the risk of an individual to have a reduced liver function with respect to using any of these substances as individual biomarkers.
  • the marker set comprises or consists of HDL or apolipoprotein A1 as a first of the at least two substances and lactate as a second of the at least two substances.
  • a biomarker set showed an AUC value of 0.87 in the training dataset (confer Figure 5A) and of 0.85 in the test dataset (confer Figure 5B).
  • combining HDL and lactate as biomarkers in the marker set significantly increases the sensitivity of determination of the risk of an individual to have a reduced liver function with respect to using any of these substances as individual biomarkers.
  • the marker set comprises or consists of HDL or apolipoprotein A1 as a first of the at least two substances and pyruvate as a second of the at least two substances.
  • a biomarker set showed an AUC value of 0.88 in the training dataset (confer Figure 6A) and of 0.85 in the test dataset (confer Figure 6B).
  • supplementing HDL with pyruvate as further biomarker in the marker set significantly increases the sensitivity of determination of the risk of an individual to have a reduced liver function with respect to using HDL as individual biomarker.
  • the marker set comprises or consists of HDL or apolipoprotein A1 as a first of the at least two substances and fumarate as a second of the at least two substances.
  • a biomarker set showed an AUC value of 0.88 in the training dataset (confer Figure 7A) and of 0.84 in the test dataset (confer Figure 7B).
  • supplementing HDL with fumarate as further biomarker significantly increases the sensitivity of determination of the risk of an individual to have a reduced liver function with respect to using HDL as individual biomarker.
  • the marker set comprises or consists of valine as a first of the at least two substances and lactate as a second of the at least two substances.
  • a biomarker set showed an AUC value of 0.84 in the training dataset (confer Figure 8A) and of 0.81 in the test dataset (confer Figure 8B).
  • valine and lactate as biomarkers in the marker set significantly increases the sensitivity of determination of the risk of an individual to have a reduced liver function with respect to using any of these substances as individual biomarkers.
  • the marker set comprises or consists of valine as a first of the at least two substances and pyruvate as a second of the at least two substances.
  • a biomarker set showed an AUC value of 0.83 in the training dataset (confer Figure 9A) and of 0.81 in the test dataset (confer Figure 9B).
  • combining pyruvate and valine as biomarkers in the marker set significantly increases the sensitivity of determination of the risk of an individual to have a reduced liver function with respect to using any of these substances as individual biomarkers.
  • the marker set comprises or consists of lactate as a first of the at least two substances and pyruvate as a second of the at least two substances.
  • a biomarker set showed an AUC value of 0.80 in the training dataset (confer Figure 10A) and of 0.78 in the test dataset (confer Figure 10B).
  • the marker set comprises or consists of HDL or apolipoprotein A1 as a first of the at least two substances and valine and pyruvate as further substances of the at least two substances.
  • a biomarker set showed an AUC value of 0.89 in the training dataset (confer Figure 11 A) and of 0.86 in the test dataset (confer Figure 11 B).
  • using a combination of the three substances HDL, valine, and pyruvate still slightly increases the sensitivity of determination of the risk of an individual to have a reduced liver function with respect to using only two of these substances.
  • the marker set comprises or consists of HDL or apolipoprotein A1 as a first of the at least two substances and valine and lactate as further substances of the at least two substances.
  • a biomarker set showed an AUC value of 0.89 in the training dataset (confer Figure 12A) and of 0.85 in the test dataset (confer Figure 12B).
  • HDL, valine, and lactate still slightly increases the sensitivity of determination of the risk of an individual to have a reduced liver function with respect to using only two of these substances.
  • the marker set comprises or consists of valine, pyruvate, and lactate.
  • Such a biomarker set showed an AUC value of 0.86 in the training dataset (confer Figure 13A) and of 0.83 in the test dataset (confer Figure 13B).
  • valine, pyruvate, and lactate still slightly increases the sensitivity of determination of the risk of an individual to have a reduced liver function with respect to using only two of these substances.
  • the present invention relates to the further medical use of a marker or a defined marker set for in-vivo diagnostics of having a reduced liver function.
  • the marker is chosen from a first group consisting of high-density lipoprotein, apolipoprotein A1 , valine, and lactate.
  • the marker set comprises or consists of at least two (e.g., 2, 3, 4, 5, 6) substances that are chosen from a second group consisting of high-density lipoprotein, apolipoprotein A1 , valine, lactate, pyruvate, and fumarate.
  • the present invention relates to a method for analyzing an isolated body fluid sample in vitro, comprising the steps explained in the following. This method is carried out on an isolated body fluid sample originating from an individual.
  • the concentration of a single substance or of at least two substances is determined by analyzing the body fluid sample with a suited measuring technique.
  • the single substance is chosen from a first group consisting of high-density lipoprotein, apolipoprotein A1 , valine, and lactate.
  • the at least two (e.g., 2, 3, 4, 5, 6) substances are chosen from a second group consisting of high-density lipoprotein, apolipoprotein A1 , valine, lactate, pyruvate, and fumarate.
  • a score is calculated from the determined concentrations, wherein the score is indicative for the risk of the individual to have a reduced liver function.
  • the score can be calculated by taking into consideration the concentrations measured or expected in a body fluid sample from a control group.
  • the score can be the median of the concentration ratios of the at least two substances between the body fluid test sample of the patient and corresponding control values of a body fluid control sample that have been measured in the past. If the score is above or below a predetermined threshold value, a significant increase or decrease of the marker substances is present in the body fluid test sample that is indicative for having a reduced liver function. It should be noted that other calculation methods as well as a weighting of individual marker concentrations with respect to other marker concentrations can also be performed in an embodiment.
  • Parameter “I” can be, e.g., the signal intensity or signal integral of an according signal observed in the evaluated measuring result.
  • “I” can be the signal intensity or signal integral of an NMR signal in an NMR spectrum if NMR spectroscopy is used as measuring technique.
  • “I” is a ratio between two signal intensities or two signal integrals. In such a case, it is, e.g., possible to standardize the concentration of a first substance (or a plurality of substances) by the concentration of a second substance.
  • the score is a (semi-)quantitative measure for the likelihood that the individual has a reduced liver function.
  • the score serves for (semi-)quantitatively determining the risk of a reduced liver function.
  • Calculating the score comprises multiplying each of the concentrations of the substances by a substance-specific weighting factor to provide a plurality of weighted values and combining the weighted values into a risk equation. Afterwards, an output of the risk equation is compared to a predefined threshold. If the score is above the threshold, there is a likelihood that the individual has a reduced liver function. In an embodiment, the likelihood and/or the risk is higher, the higher the score is (i.e., the likelihood and/or the risk increases with increasing distance of the score from the threshold).
  • the calculated score is output and presented to the individual and/or to a third person such as a physician or medical staff.
  • the output can be performed on a display (i.e., in an electronic way) or in printed form.
  • a report indicating the score, optionally in combination with a comparative scale of possible scores and their meaning with respect to the risk of having a reduced liver function.
  • the method is a computer-implemented method.
  • all steps of spectral analysis and concentration determination as well as of score calculation are performed on a computer.
  • Such steps are far too complex to be done in a manual way.
  • the computer- implemented concentration determination is, in an embodiment, based on a spectral analysis, such as an analysis of NMR spectra.
  • the spectral analysis and the further required steps until the score can be output can be done on the same computer that is used for controlling a spectrometer performing the spectral analysis or on a different computer.
  • the body fluid sample is a urine sample or a blood sample.
  • the blood sample is a whole blood sample, a blood serum sample, a blood plasma sample, or any other blood preparation derivable from whole blood or from other blood preparations.
  • Blood serum is a particularly appropriate body fluid for carrying out the method or for the above-mentioned in vitro or in vivo uses of specific biomarkers contained in the marker set.
  • Blood plasma is also an appropriate body fluid.
  • lactate is present in the marker set if blood plasma is used as body fluid to be analyzed.
  • the body fluid sample (and therewith the patient from whom the body fluid sample originates) is grouped into one of at least two predefined groups based on the calculated score.
  • one group encompasses patients having a reduced liver function, wherein the other group encompasses individuals having a preserved liver function.
  • reduced liver function and “preserved liver function” are defined above in detail.
  • the resulting grouping can also be indicated on an according report.
  • the grouping encompasses more than two groups (yes/no), namely information on the grade of severity of the reduced liver function.
  • the individual of whom the body fluid is analyzed is a healthy individual.
  • the individual is a risk patient, i.e., an individual belonging to a group that has an increased risk of having a reduced liver function with respect to the risk of a healthy standard population.
  • the individual suffers from (etiology-independent) cirrhosis.
  • the individual is a patient having cirrhosis but being asymptomatic.
  • the individual suffers from a (in particular chronic) viral liver infection and has a cirrhosis.
  • the individual suffers from chronic hepatitis B and has a cirrhosis.
  • the individual suffers from chronic hepatitis C and has a cirrhosis.
  • the individual suffers from non-alcoholic fatty liver disease (NAFLD), in particular from non-alcoholic steatohepatitis (NASH), and has a cirrhosis.
  • NAFLD non-alcoholic fatty liver disease
  • NASH non-alcoholic steatohepatitis
  • the individual suffers from alcoholic liver disease and has a cirrhosis.
  • the individual has a cryptogenic cirrhosis.
  • the individual suffers from a (in particular chronic) viral liver infection without having a cirrhosis.
  • the individual suffers from chronic hepatitis B without having a cirrhosis.
  • the individual suffers from grade IV fibrosis (i.e., a fibrosis that led to cirrhosis). All of the precedingly mentioned embodiments can be particularly well combined so that the individual may be chosen from any of the beforementioned groups of patients/healthy individuals.
  • the score is calculated by not only considering the concentration of the at least two marker substances but also includes the age and/or the gender of the individual who donated the body fluid sample.
  • calculating the score involves calculating a ratio between at least two concentration values.
  • a ratio between HDL and valine or between pyruvate and lactate is calculated in an embodiment.
  • individual ratios of pairs of two of all marker substances the concentrations of which have been determined upon carrying out the method can be calculated for calculating the score.
  • the present invention relates to a medical method for diagnosing a reduced liver function in an individual.
  • the method comprises the steps explained in the following.
  • a body fluid sample is gathered from an individual.
  • the concentration of a single substance or of at least two substances is determined by analyzing the body fluid sample with a suited measuring technique.
  • the single substance is chosen from a first group consisting of high-density lipoprotein, apolipoprotein A1 , valine, and lactate.
  • the at least two (e.g., 2, 3, 4, 5, 6) substances are chosen from a second group consisting of high- density lipoprotein, apolipoprotein A1 , valine, lactate, pyruvate, and fumarate.
  • a score is calculated from the determined concentrations, wherein the score is indicative for determining the risk of the individual to have a reduced liver function.
  • the present invention relates to a decision support system for analyzing an isolated body fluid sample in vitro, the decision support system comprising: a) a unit for providing a body fluid sample from an individual; b) a unit for determining the concentration of a single substance or of at least two substances by analyzing the body fluid sample with a suited measuring technique.
  • the single substance is chosen from a first group consisting of high-density lipoprotein, apolipoprotein A1 , valine, and lactate.
  • the at least two (e.g., 2, 3, 4, 5, 6) substances are chosen from a second group consisting of high-density lipoprotein, apolipoprotein A1 , valine, lactate, pyruvate, and fumarate; and c) a unit for calculating a score from the determined concentrations, the score being indicative for determining the risk of the individual to have a reduced liver function.
  • the unit for determining the concentration of the single substance or of the at least two substances is configured to determine the concentration of any exemplary substance or substance combination of the embodiments explained above.
  • All embodiments of the use of the marker or the marker set can be combined in any desired way and can be transferred either individually or in any arbitrary combination to the further medical use of the marker or the marker set as well as to the different methods and to the decision support system.
  • all embodiments of the further medical use of the marker or the marker set can be combined in any desired way and can be transferred either individually or in any arbitrary combination to the use of the marker or the marker set, to the different methods, and to the decision support system.
  • all embodiments of the different methods can be combined in any desired way and can be transferred either individually or in any arbitrary combination to the use of the marker or the marker set, to the further medical use of the marker or the marker set, to any other of the described methods, and to the decision support system.
  • Figures 1 A to 13B show ROC plots illustrating the ability of different markers or marker sets for determining the risk of an individual to have a reduced liver function upon evaluating a training dataset (always in Figure A) or upon evaluating a test dataset (always in Figure B); and
  • Figures 1 C to 13D show confusion matrices illustrating the distributions of calculated scores from the determined concentrations of the individual biomarkers or the biomarkers contained in the respective marker set upon evaluating a training dataset (always in Figure C) or upon evaluating a test dataset (always in Figure D).
  • the case group consisted of patients classified as having a reduced liver function (i.e., being classified into Child-Pugh class A and having ascites; or being classified into Child-Pugh classes B or C (irrespective of having ascites)).
  • the control group consisted of patients classified into Child-Pugh class A without having ascites
  • Table A Details of the tested patient cohort.
  • the AXINON® serum calibrator 2.0 was filled into an NMR tube.
  • a cap for NMR tubes was placed onto the NMR tube. Subsequently, the calibration sample was placed in a defined position of an NMR rack. b) Control samples
  • the AXINON® serum control 2.0 was filled into an NMR tube.
  • a cap for NMR tubes was placed onto the NMR tube.
  • two control samples were placed in defined positions of the same NMR rack.
  • c) Analytical samples The AXINON® serum additives solution 2.0 was combined with the blood serum to be analyzed in a ratio of 1 :10 in a suitable reagent container. The liquid was gently mixed, wherein foaming was avoided. The volume of the mixture required for the NMR measurement was transferred into an NMR tube.
  • a cap for NMR tubes was placed onto the NMR tube.
  • Each analytical sample was placed at a defined position into the same NMR rack according to a rack list (as defined by the AXINON® Sample Wizard, see AXINON® Sample Wizard User manual). Attention was paid to ensure proper positioning of the samples. The analysis results of samples that were not clearly assignable were discarded.
  • Samples were measured in batches of up to 93 analytical samples per run.
  • each run included one AXINON® blood serum calibrator sample and two AXINON® blood serum control samples (before and after the analytical blood serum samples, respectively) to assure ideal measurement conditions throughout the run.
  • NMR spectra underwent automatic referencing, phase correction and baseline correction before further analysis.
  • the NMR spectra underwent an automatic standardization and calibration procedure to minimize between-device, between-day and between-run effects.
  • the quality of each of these spectra was assessed by a custom spectrum qualification algorithm that analyzes general spectral properties, e.g., offset and tilt of the baseline in selected spectral regions, and properties of selected indicator signals, e.g., signal position, shape and width. Spectra that did not meet the predefined quality criteria were excluded from further analysis.
  • spectral properties e.g., offset and tilt of the baseline in selected spectral regions
  • properties of selected indicator signals e.g., signal position, shape and width.
  • the cohort i.e., the plurality
  • the cohort was checked for regions in which the cohort did not show a significant number of signals. These regions - like the region of the water signal and the regions in which signals are contained that originate from substances contained in AXINON® serum additives - were ignored in the steps explained in the following.
  • the remaining spectral regions were subject to an adaptive binning, which divides the spectrum in bins of differing size or extent (typically covering 0.01 to 0.05 ppm, but in extreme cases also covering 0.005 to 0.5 ppm).
  • the resulting boundaries for the bins are tailored to represent signals and/or signal structures in the spectrum as good as possible.
  • Quantification of substances was done by fitting a predefined, characteristic set of PseudoVoigt functions, which represent a linear combination of a Gaussian and a Lorentzian function, to the substance specific signal structure(s). The resulting signal fits were checked for goodness of fit and physical plausibility of properties related to fit parameters in order to reject results of insufficient fit quality.
  • quantification models making use of the previously assigned bins were applied. After substance identification, substance labels have been assigned to these bins. The quantification was then determined by the bin value, which calculates as [(sum of intensities in bin)/(number of data points in bin)]. The standardization by data points is used to compensate for a varying number of data points in the bins. The number of data points in a bin may vary by one data point due to shifts of the applied discretization grid. In either case, the resulting integral of the quantification is then translated into a substance concentration by applying a conversion factor which has been determined experimentally for each of the substances.
  • the identified marker substances were tested in different combinations to assess their suitability for determining the risk of an individual of having a reduced liver function. In doing so, the result of the determination based on the marker substances (predicted risk) has been checked against clinical signs of a reduced liver function in the patient who donated the serum sample, as already explained above.
  • ROC receiver operating characteristic
  • Figures 1A, 2A, 3A, 4A, 5A, 6A, 7A, 8A, 9A, 10A, 1 1 A, 12A, and 13A show ROC plots of different individual markers or marker combinations upon evaluation of a training dataset.
  • Figures 1 C, 2C, 3C, 4C, 5C, 6C, 7C, 8C, 9C, 10C, 11 C, 12C, and 13C show the corresponding confusion matrices based on the scores assigned to the patient’s health status (i.e., having a preserved liver function or a reduced liver function) confirmed by other tests.
  • Figures 1 B, 2B, 3B, 4B, 5B, 6B, 7B, 8B, 9B, 10B, 1 1 B, 12B, and 13B show ROC plots of different individual markers or marker combinations upon evaluation of a test dataset.
  • Figures 1 D, 2D, 3D, 4D, 5D, 6D, 7D, 8D, 9D, 10D, 11 D, 12D, and 13D show the corresponding confusion matrices based on the scores assigned to the patient’s health status (i.e., having a preserved liver function or a reduced liver function) confirmed by other tests.
  • Table 1 Summary of biomarkers/biomarker set composition and corresponding AUC values depicted in the Figures.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne, entre autres, l'utilisation d'un marqueur ou d'un ensemble de marqueurs dans une méthode in vitro pour déterminer le risque qu'un individu présente une fonction hépatite réduite. Le marqueur est choisi parmi un premier groupe constitué de lipoprotéine haute densité, d'apolipoprotéine A1, de valine et de lactate; l'ensemble de marqueurs comprend au moins deux substances choisies dans un second groupe constitué de lipoprotéine haute densité, d'apolipoprotéine A1, de valine, de lactate, de pyruvate et de fumarate.
PCT/EP2024/068885 2023-07-06 2024-07-04 Utilisation d'un marqueur ou d'un ensemble de marqueurs pour déterminer le risque qu'un individu présente une fonction hépatique réduite Ceased WO2025008467A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102023117863.6 2023-07-06
DE102023117863 2023-07-06

Publications (2)

Publication Number Publication Date
WO2025008467A2 true WO2025008467A2 (fr) 2025-01-09
WO2025008467A3 WO2025008467A3 (fr) 2025-02-13

Family

ID=91961820

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/068885 Ceased WO2025008467A2 (fr) 2023-07-06 2024-07-04 Utilisation d'un marqueur ou d'un ensemble de marqueurs pour déterminer le risque qu'un individu présente une fonction hépatique réduite

Country Status (1)

Country Link
WO (1) WO2025008467A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012045773A9 (fr) 2010-10-06 2012-10-18 Lipofit Analytic Gmbh Procédé de caractérisation d'un échantillon par analyse de données
US20170370954A1 (en) 2014-11-19 2017-12-28 Metabolon, Inc. Biomarkers for Fatty Liver Disease and Methods Using the Same
US20200378991A1 (en) 2016-05-29 2020-12-03 Human Metabolomics Institute, Inc. Liver disease-related biomarkers and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012045773A9 (fr) 2010-10-06 2012-10-18 Lipofit Analytic Gmbh Procédé de caractérisation d'un échantillon par analyse de données
US20170370954A1 (en) 2014-11-19 2017-12-28 Metabolon, Inc. Biomarkers for Fatty Liver Disease and Methods Using the Same
US20200378991A1 (en) 2016-05-29 2020-12-03 Human Metabolomics Institute, Inc. Liver disease-related biomarkers and methods of use thereof

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
ALBERS, I. ET AL.: "Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis", SCAND J GASTROENTEROL, vol. 24, no. 3, 1989, pages 269 - 76
DOVE, L.R. BROWN: "Liver transplantation in adults: Patient selection and pretransplantation evaluation. UpToDate 2021", ACCESSED, 20 February 2023 (2023-02-20)
FERENCI, P.: "Diagnosis of minimal hepatic encephalopathy: still a challenge", GUT, vol. 62, no. 10, 2013, pages 1394
GALLE, P. ET AL.: "European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma", J HEPATOL, vol. 69, no. 1, 2018, pages 182 - 236
GARRISON, R.N. ET AL.: "Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis", ANN SURG, vol. 199, no. 6, 1984, pages 648 - 55
GEISEL, D. ET AL.: "Imaging-based evaluation of liver function: comparison of (9)(9)mTc-mebrofenin hepatobiliary scintigraphy and Gd-EOB-DTPA-enhanced MRI", EUR RADIOL, vol. 25, no. 5, 2015, pages 1384 - 91, XP035479322, DOI: 10.1007/s00330-014-3536-8
GOLDBECKER, A. ET AL.: "Comparison of the most favoured methods for the diagnosis of hepatic encephalopathy in liver transplantation candidates", GUT, vol. 62, no. 10, 2013, pages 1497 - 504
GOWDA, S. ET AL.: "A review on laboratory liver function tests", PAN AFR MED J, vol. 3, 2009, pages 17
INFANTE-RIVARD, C.S. ESNAOLAJ.P. VILLENEUVE: "Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics", HEPATOLOGY, vol. 7, no. 4, 1987, pages 660 - 4
KHOLOUSSY, A.M.D. POLLACKT. MATSUMOTO: "Prognostic significance of indocyanine green clearance in critically ill surgical patients", CRIT CARE MED, vol. 12, no. 2, 1984, pages 115 - 6
NILSSON, H. ET AL.: "Gd-EOB-DTPA-enhanced MRI for the assessment of liver function and volume in liver cirrhosis", BR J RADIOL, vol. 86, no. 1026, 2013, pages 20120653, XP055225154, DOI: 10.1259/bjr.20120653
PUGH, R.N. ET AL.: "Transection of the oesophagus for bleeding oesophageal varices", BR J SURG, vol. 60, no. 8, 1973, pages 646 - 9, XP008121280, DOI: 10.1002/bjs.1800600817
REIG, M. ET AL.: "BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update", J HEPATOL, vol. 76, no. 3, 2022, pages 681 - 693, XP086961925, DOI: 10.1016/j.jhep.2021.11.018
SIMONOVSKY, V.: "The diagnosis of cirrhosis by high resolution ultrasound of the liver surface", BR J RADIOL, vol. 72, no. 853, 1999, pages 29 - 34
SMITH, A. ET AL.: "Liver Disease: Evaluation of Patients With Abnormal Liver Test Results", FP ESSENT, vol. 511, 2021, pages 11 - 22
SULLIVAN, M.K.H.B. DAHERD.C. ROCKEY: "Normal or near normal aminotransferase levels in patients with alcoholic cirrhosis", AM J MED SCI, vol. 363, no. 6, 2022, pages 484 - 489
VOS, J.J. ET AL.: "Green light for liver function monitoring using indocyanine green? An overview of current clinical applications", ANAESTHESIA, vol. 69, no. 12, 2014, pages 1364 - 76, XP071010222, DOI: 10.1111/anae.12755

Also Published As

Publication number Publication date
WO2025008467A3 (fr) 2025-02-13

Similar Documents

Publication Publication Date Title
Johnsen et al. Insulin-like growth factor (IGF) I,-II, and IGF binding protein-3 and risk of ischemic stroke
Kellman et al. T1 and extracellular volume mapping in the heart: estimation of error maps and the influence of noise on precision
JPWO2016163539A1 (ja) 肝疾患の病態を判別する方法
US10076246B2 (en) Method and apparatus for noninvasive quantitative detection of fibrosis in normal and viable myocardium by MRI
Kammerlander et al. Extracellular volume quantification by cardiac magnetic resonance imaging without hematocrit sampling: ready for prime time?
Jerban et al. Quantitative magnetic resonance imaging of cortical and trabecular bone
Okujava et al. Measurement of temporal lobe T2 relaxation times using a routine diagnostic MR imaging protocol in epilepsy
Mirzai et al. Skeletal muscle quantity and quality evaluation in heart failure: comparing thoracic versus abdominopelvic CT approaches
DK2674761T3 (en) PC-44 O: 4 - biomarker for visceral obesity
Wang et al. Dual-layer spectral-detector CT for detecting liver steatosis by using proton density fat fraction as reference
WO2025008467A2 (fr) Utilisation d'un marqueur ou d'un ensemble de marqueurs pour déterminer le risque qu'un individu présente une fonction hépatique réduite
WO2025008465A2 (fr) Utilisation d'un biomarqueur pour déterminer le score de child-pugh selon lequel un individu doit être classé
US20210318337A1 (en) Biomarkers for Precisely Predicting the Glomerular Filtration Rate and for Indicating Pathophysiologic Factors of an Impaired Glomerular Filtration Rate
DK2867680T3 (en) PC O 44: 6 - biomarker for visceral obesity
JP6243413B2 (ja) Ｐｃ−ｏ４２：４−内臓脂肪過多のバイオマーカー
WO2025008464A2 (fr) Utilisation d'un marqueur ou d'un ensemble de marqueurs pour déterminer le risque pour un individu de souffrir d'ascite
JP2025539270A (ja) 大動脈解離患者の予後予測製品の製造における血清可溶性ｓｔ２の使用、および関連する予測装置
Paglinawan et al. Measurement of specific gravity, urobilinogen, blood, protein and pH level of urine samples using raspberry Pi based portable urine test strip analyzer
WO2025008466A1 (fr) Utilisation d'un biomarqueur pour déterminer le risque d'encéphalopathie hépatique chez un individu
CN106716123B (zh) 冠心病患者特异性生物标志组合物及其用途
Lundin et al. Detection of myocarditis using T1 and ECV mapping is not improved by early compared to late post‐contrast imaging
Ferreira et al. Quantification methods for 99mTc-labelled disphosphonates uptake in cardiac amyloidosis
Tan et al. Novel Algorithm to Estimate Fat‐Free Muscle Volumes in Women Using the Urinary Deuterated‐Creatine Dilution Method
Costa et al. Clinical validation of a fully automated framework for ventricular segmentation and wall motion classification from cine CMR
US20220412992A1 (en) Method for making a finding for the functionality of an anorexigenic signal path for a patient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24745895

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2024745895

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024745895

Country of ref document: EP

Effective date: 20260206